ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

08 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Announces Pricing of Public Offering of Common Stock

09 Jun 2021 19:55:14 By Nasdaq GlobeNewswire

Aclaris Announces Proposed Public Offering of Common Stock

08 Jun 2021 16:15:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

08 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

17 May 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

07 May 2021 07:00:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

15 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

25 Feb 2021 07:00:04 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

22 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

10 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Announces Pricing of Public Offering of Common Stock

20 Jan 2021 08:45:00 By Nasdaq GlobeNewswire

Aclaris Announces Proposed Public Offering of Common Stock

19 Jan 2021 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

19 Jan 2021 07:00:00 By Nasdaq GlobeNewswire